Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;116(1):176-181.
doi: 10.1111/add.15082. Epub 2020 Apr 28.

Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study

Jonathan Schimmel  1   2 , Elise Amioka  1 , Karilynn Rockhill  1 , Colleen M Haynes  1 , Joshua C Black  1 , Richard C Dart  1 , Janetta L Iwanicki  1
Affiliations

Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study

Jonathan Schimmel et al. Addiction. 2021 Jan.

Abstract

Background and aims: Mitragyna speciosa ('kratom') contains mu opioid partial agonists. It is widely available, and occasionally used as a home remedy for opioid use disorder. The Drug Enforcement Agency considers kratom a drug of concern; however, prevalence of use and role in drug misuse are unknown. This study aimed to characterize kratom use in the United States.

Design: Cross-sectional Survey of Non-Medical Use of Prescription Drugs (NMURx) Program, 2018 third quarter and 2019 first quarter.

Setting: A validated non-probability online survey in the United States.

Participants: A total of 59 714 respondents aged 18 years or older, weighted to represent the adult US population (n = 252 063 800).

Measurements: In addition to prevalence of past-year kratom and other drug use, behavior proportions were estimated. The Drug Abuse Screening Test (DAST-10) estimated consequences of drug abuse.

Findings: The estimated prevalence of past-year kratom use in the adult US population was 0.8% [95% confidence interval (CI) = 0.7-0.9], representing 2 031 803 adults. Life-time prevalence was 1.3% (95% CI = 1.2-1.4), representing 3 353 624 adults. Kratom users were younger (mean 35 years, P < 0.001), with higher proportions of males (61.0 versus 48.6%, P < 0.001), students (14.1 versus 7.5%, P < 0.001) and health-care professionals (9.7 versus 4.5%, P < 0.001) and fewer bachelor's/advanced degree graduates (33.4 versus 42.6%, P < 0.001) compared with non-users. Results were inconclusive on whether there was a difference in kratom use by race, household income or employment status. Among those with past-year kratom use, 36.7% (95% CI = 32.1-41.3) non-medically used prescription opioids, 21.7% (95% CI = 18.0-25.5) used illicit opioids, 54.4% (95% CI = 49.5-59.3) used another illicit drug and 67.1% (95% CI = 62.5-71.8) used cannabis. The DAST-10 profile was more often substantial/severe in kratom users (21 versus 1%, P < 0.001) compared with non-users.

Conclusions: Estimated United States past-year prevalence of kratom use is 0.8%, and kratom users tend to have more serious substance abuse profiles than non-users or users of cannabis, alcohol or cigarettes. To our knowledge, this is the first description of kratom use at the national level.

Keywords: Drug Abuse Screening Test; Mitragyna speciosa; NMURx; epidemiology; kratom; mitragynine; opioid use disorder; opioids; patterns of use; prevalence.

PubMed Disclaimer

Comment in

References

    1. Kruegel A. C., Gassaway M. M., Kapoor A., Varadi A., Majumdar S., Filizola M. et al. Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc 2016; 138: 6754-6764.
    1. Corkery J. M., Streete P., Claridge H., Goodair C., Papanti D., Orsolini L. et al. Characteristics of deaths associated with kratom use. J Psychopharmacol 2019; 33: 1102-1123.
    1. Boyer E. W., Babu K. M., Macalino G. E. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict 2007; 16: 352-356.
    1. Forrester M. B. Kratom exposures reported to Texas poison centers. J Addict Dis 2013; 32: 396-400.
    1. Post S., Spiller H. A., Chounthirath T., Smith G. A. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol 2019; 57: 847-854.

LinkOut - more resources